Literature DB >> 32016091

Dual specificity phosphatase 6 as a new therapeutic target candidate for epithelial ovarian cancer.

Seiya Sato1, Hiroaki Itamochi2.   

Abstract

Entities:  

Year:  2019        PMID： 32016091      PMCID： PMC6976391          DOI： 10.21037/atm.2019.12.105

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  24 in total

1.  Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.

Authors:  Annmarie Ramkissoon; Katherine E Chaney; David Milewski; Kyle B Williams; Rory L Williams; Kwangmin Choi; Adam Miller; Tanya V Kalin; Joseph G Pressey; Sara Szabo; Mohammad Azam; David A Largaespada; Nancy Ratner
Journal:  Clin Cancer Res       Date:  2019-04-01       Impact factor: 12.531

Review 2.  Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy.

Authors:  I Bernard Weinstein; Andrew K Joe
Journal:  Nat Clin Pract Oncol       Date:  2006-08

3.  Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Authors:  Robert A Burger; Mark F Brady; Michael A Bookman; Gini F Fleming; Bradley J Monk; Helen Huang; Robert S Mannel; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Michael J Birrer; Sharon X Liang
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

Review 4.  Oncogene addiction: setting the stage for molecularly targeted cancer therapy.

Authors:  Sreenath V Sharma; Jeffrey Settleman
Journal:  Genes Dev       Date:  2007-12-15       Impact factor: 11.361

5.  Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells.

Authors:  David W Chan; Vincent W S Liu; George S W Tsao; Kwok-Ming Yao; Toru Furukawa; Karen K L Chan; Hextan Y S Ngan
Journal:  Carcinogenesis       Date:  2008-07-16       Impact factor: 4.944

6.  (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.

Authors:  Christine A Pratilas; Barry S Taylor; Qing Ye; Agnes Viale; Chris Sander; David B Solit; Neal Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-27       Impact factor: 11.205

Review 7.  Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling.

Authors:  Christopher J Caunt; Stephen M Keyse
Journal:  FEBS J       Date:  2012-08-28       Impact factor: 5.542

8.  Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.

Authors:  Fan Wu; Robert D McCuaig; Christopher R Sutton; Abel H Y Tan; Yoshni Jeelall; Elaine G Bean; Jin Dai; Thiru Prasanna; Jacob Batham; Laeeq Malik; Desmond Yip; Jane E Dahlstrom; Sudha Rao
Journal:  Int J Mol Sci       Date:  2019-06-24       Impact factor: 5.923

9.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245

Review 10.  The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs).

Authors:  Andrew M Kidger; Stephen M Keyse
Journal:  Semin Cell Dev Biol       Date:  2016-01-11       Impact factor: 7.727
View more
  1 in total

1.  DUSP7 inhibits cervical cancer progression by inactivating the RAS pathway.

Authors:  Huimin Bai; Meiying Song; Ruili Jiao; Weihua Li; Jing Zhao; Meizhu Xiao; Mulan Jin; Zhengyu Zhang; Haiteng Deng
Journal:  J Cell Mol Med       Date:  2021-08-26       Impact factor: 5.310
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.